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Abstract
Background: With advances in the treatment of sepsis, the systemic inflammatory response syndrome (SIRS) has
been losing its prognostic power. Since the SIRS category is no longer used for the diagnosis of sepsis, the
disseminated intravascular coagulation (DIC) diagnostic criteria released by Japanese Association for Acute Medicine
(JAAM) should be modified. Thus, the purpose of this study was to examine the appropriateness of replacing the
SIRS score with antithrombin activity in JAAM-DIC diagnostic criteria.
Methods: We analyzed data from 819 septic patients who had received recombinant thrombomodulin. The
relationships between the 28-day mortality rate and baseline laboratory and clinical parameters were examined
using univariate and multivariate analyses, and the impact of replacing the SIRS criteria with antithrombin activity
was evaluated.
Results: The SIRS score, prothrombin time ratio, and antithrombin activity were associated with the 28-day
mortality rate (P values = 0.013, 0.018, and 0.003, respectively, by multivariate analysis). A modified version of the
JAAM-DIC diagnostic criteria using an antithrombin activity <70 % was capable of diagnosing the identical number
(n = 706) and a similar severity of patients (mortality, 34.6 % versus 34.8 %).
Conclusion: Since anticoagulant therapy is expected to be more effective in patients with more severe coagulation
disorders, the modified version of the JAAM-DIC diagnostic criteria might be useful for discriminating patients with
sepsis who are good candidates for anticoagulant therapy.
Keywords: Disseminated intravascular coagulation, Sepsis, Antithrombin activity, Systemic inflammatory response
syndrome, Anticoagulant
Background
Recent advances in therapeutic strategies have signifi-
cantly improved the outcomes of sepsis patients. The
need for anticoagulant therapy for sepsis-associated dis-
seminated intravascular coagulation (DIC) has long
been discussed. A number of studies demonstrated that
the efficacy of anticoagulant treatments such as
antithrombin and thrombomodulin is limited to septic
patients with concomitant DIC especially in the pres-
ence of severe coagulation disorders [1–5].
Among the criteria used to diagnose DIC, Japanese
Association for Acute Medicine criteria (JAAM-DIC)
have consistently shown higher sensitivity and pre-
dictive accuracy for mortality compared to other
DIC criteria [6, 7]. One of the reasons hypothesized
to explain the better performance of the JAAM-DIC
was the inclusion of the systemic inflammatory re-
sponse syndrome (SIRS) score within the JAAM-
DIC. The SIRS was introduced as one of the criteria
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to diagnose sepsis in 1992 and has been used as a
marker of disease severity [8]. In recent years, how-
ever, the prognostic relevance of the SIRS score has
been questioned [9], and SIRS criteria have been
omitted from the latest definition of sepsis proposed
in 2016 [10]. Another problem associated with in-
cluding the SIRS score in the diagnostic criteria for
DIC was that this item does not directly reflect the
presence of a coagulation/fibrinolysis disorder; thus,
its use in DIC diagnostic criteria might no longer be
appropriate. Thus, we intend to replace the SIRS
score with another item to maintain the usefulness
of DIC criteria in making decisions regarding the ap-
plication of anticoagulant therapy.
Levels of antithrombin decrease in sepsis due to exces-
sive thrombin generation [11], increased vascular leakage,
and impaired synthesis and degradation by proteases [12,
13]. A lower antithrombin activity has repeatedly been re-
ported in severe sepsis [14, 15] with a significant associ-
ation with poor survival [16–18]. The measurement of
antithrombin activity has become routinely available in
most of the laboratories in Japan, and the Japanese
Association for Thrombosis and Hemostasis (JSTH)
proposed new DIC diagnostic criteria which include
antithrombin activity (https://www.jstage.jst.go.jp/art-
icle/jjsth/25/5/25_629/_pdf ). Despite the role of anti-
thrombin in the coagulation cascade and the
prognostic value of antithrombin levels in septic pa-
tients, none of the DIC diagnostic scores has evalu-
ated the inclusion of antithrombin activity among
the diagnostic criteria. In the present study, we
replaced the SIRS criteria with the antithrombin ac-
tivity in the JAAM-DIC diagnostic criteria and ex-
amined the characteristics of this new, modified
version of the JAAM-DIC.
Methods
Data collection
The data set was obtained from a post-marketing survey
of recombinant human soluble thrombomodulin (TM-α;
Asahi Kasei Parma Corporation, Tokyo, Japan) per-
formed by the Asahi Kasei Pharma Corporation between
May 2008 and March 2010 [19] and was provided by the
JSTH.
A total of 2516 Japanese patients with infection-
associated coagulation disorder were registered in this
survey; however, since the measurement of antithrombin
activity was not mandatory in the protocol, a complete
data set was obtained in 819 cases, and all of these pa-
tients were analyzed in this study. Many were admitted
because of severe infection, but patients with sepsis were
also included. All patients were treated with TM-α;
patients who received any other anticoagulants prior to
recombinant thrombomodulin treatment were excluded.
Other exclusion criteria were as follows: patients with
SIRS score ≦1, missing data for complete analysis, un-
known outcome, hypersensitivity to TM-α, and preg-
nancy. The use of anti-platelets was permitted. The
survey was conducted in accordance with the Declar-
ation of Helsinki and Good Vigilance Practice and Good
Post-marketing Study Practice.
Laboratory measurements
The platelet count, fibrinogen/fibrin degradation products
(FDP), prothrombin time (PT), and antithrombin activity
were measured in local laboratories. To measure the anti-
thrombin activity, the plasma anti-Factor Xa activity or
the anti-thrombin activity was assessed (chromogenic sub-
strate method, reference intervals: 70–120 %).
Statistical analysis
The relationship between the 28-day mortality and each
component of the JAAM-DIC criteria (i.e., SIRS score,
platelet count, FDP, and PT ratio) and the antithrombin ac-
tivity at baseline (day of DIC diagnosis) were examined by
univariate analysis in a logistic regression model. Variables
associated with 28-day mortality at a P level of less than
0.05 were analyzed using a multivariate analysis (standard
method of logistic regression analysis). The analysis was
conducted using the outcome (survived, 0; died, 1) as the
criterion variate and the SIRS score, platelet count, PT ra-
tio, FDP, and antithrombin activity as explanatory variates.
The differences in mortality according to various anti-
thrombin activities were examined using the χ2 test.
The numerical values in the text and tables are the
median and interquartile range (IQR), unless otherwise
noted. The results of the logistic regression analysis were
reported as the odds ratio (OR), P values, and 95 % con-
fidence interval (CI). For all the reported results, P <
0.05 was considered to denote statistical significance.
The above-mentioned analyses were performed using




Among the 819 patients, 546 patients survived
(66.7 %) and 273 patients died (33.3 %). DIC was di-
agnosed based on a score of 4 or more according to
the JAAM-DIC diagnostic criteria, and 706 cases
(86.2 %) fulfilled the JAAM-DIC criteria. Although
TM-α treatment was usually initiated after the diag-
nosis of DIC, this was not strictly regulated and was
independently decided by each physician. As a result,
113 patients did not fulfill the criteria of JAAM-DIC
at the start of treatment. Table 1 shows the baseline
characteristics of the patients. The median age of
the survivors was 69 (56 − 78) years, while that of
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the non-survivors was 72 (62 − 80) years (P = 0.007).
A significant gender difference was seen between survivors
and non-survivors. Sequential organ failure assessment
(SOFA) score, the requirement of mechanical ventilation,
and the incidence of bleeding were higher in the non-
survivors (P = 0.000, 0.000, and 0.030, respectively). The
median SIRS score was lower in survivors than in non-
survivors (P = 0.037). Regarding the coagulation profile, the
platelet count was lower (P = 0.026), the PT ratio was
higher (P < 0.001), and the antithrombin activity was lower
in non-survivors (P < 0.001). The FDP was not significantly
different between the survivors and non-survivors.
Factors associated with survival
Among the categories in JAAM-DIC, the univariate ana-
lyses showed that the patients’ baseline SIRS score (P =
0.019) and PT ratio (P = 0.002) were associated with the
outcome. Among the coagulation profiles, the baseline an-
tithrombin activity showed the strongest association with
the outcome (P = 0.000). In contrast, a significant associ-
ation was not observed between the platelet count and the
patients’ outcome (P = 0.073) or the FDP and the patients’
outcome (P = 0.586). The significant associations between
the outcome and antithrombin activity (P = 0.003), PT ra-
tio (P = 0.018), and SIRS score (P = 0.013) were also con-
firmed by multivariate analysis (Table 2).
Table 3 shows the OR of various factors to the outcome
calculated using a logistic regression analysis. The OR of a
SIRS score ≧3 and an antithrombin activity <70 % were
1.48 (P = 0.014) and 1.52 (P = 0.021), respectively.
Comparison of mortality according to various
antithrombin activities
The mortality increased as the baseline antithrombin
activity decreased, and the mortality was significantly
different at all cut-off values of 70 %, 60 %, 50 %, and
40 %. The mortality of the patients with a baseline anti-
thrombin activity ≧70 % was 26.5 %, while that of
patients with an antithrombin activity <70 % was
35.5 % (P = 0.021) (Table 4).
Comparison of original and modified JAAM-DIC diagnos-
tic criteria
The number of patients was 1.16-fold greater in the cat-
egory with an antithrombin activity <70 % (n = 623),
compared with the category with a SIRS score ≧3 (n =
538) (Fig. 1). However, the numbers of DIC patients
identified by JAAM-DIC diagnostic criteria and the
modified JAAM-DIC diagnostic criteria using antithrom-
bin activity were exactly the same. The mortalities of
these two criteria were almost identical (34.6 % versus
34.8 %) (Table 5).
Discussion
There are three popular diagnostic criteria for DIC: the
criteria of the Japanese Ministry of Health, Labour and
Welfare (JMHW) [20], those of the International Society
on Thrombosis and Haemostasis (ISTH) [21], and those
of the JAAM [6]. The JAAM-DIC criteria were designed
in 2006 to select candidates for anticoagulant therapy
[22], and “applying the anticoagulation therapy from the
early stage of DIC” was the fundamental concept [23].
Currently, antithrombin and recombinant thrombomo-
dulin are the primary anticoagulants recommended in
the Japanese guidelines [24]; however, some recent stud-
ies have demonstrated that the JAAM-DIC cannot dis-
criminate candidates for recombinant thrombomodulin
treatment [4, 25, 26]. Yamakawa et al. [25] reported that
the probability of a beneficial effect from recombinant
thrombomodulin increased as the baseline severity in-
creased, and the JAAM-DIC category was not






Age, years 69 (56 − 78) 72 (62 − 80) 0.007
Gender, male/female 285/261 175/98 0.001
Body weight, kg 51.8 (44.6 − 61.2) 53.0 (45.0 − 62.0) 0.580
DIC score 5 (4 − 7) 6 (4 − 7) 0.183
SOFA score 9 (6 − 12) 12 (8 − 14) 0.000
Mechanical ventilation,
n (%)
160 (29.3) 159 (58.3) 0.000
SIRS score 3 (2 − 4) 3 (2 − 4) 0.037
SIRS score ≧ 3, n (%) 343 (62.8) 195 (71.4) 0.000
Bleeding symptoms, n (%) 69 (12.6) 50 (18.3) 0.030
Coagulation parameters
Platelet count, ×109/L 6.7 (3.8 − 10.2) 5.9 (3.2 − 8.9) 0.026
FDP, μg/mL 28.0 (13.2 − 50.1) 24.9 (11.1 − 44.6) 0.095
PT ratio 1.31 (1.17 − 1.50) 1.42 (1.22 − 1.70) 0.000
AT activity, n (%) 56 (44 − 70) 51 (36 − 65) 0.000
Continuous variables are given as median (interquartile range)
AT antithrombin, DIC disseminated intravascular coagulation, FDP fibrinogen/
fibrin degradation products, PT prothrombin time, SIRS systemic inflammatory
response syndrome, SOFA sequential organ failure assessment
Table 2 Relationship between 28-day mortality and JAAM-DIC
criteria at baseline
Item Univariate Multivariate
OR 95 % CI P value OR 95 % CI P value
SIRS score 1.18 1.03 − 1.37 0.019 1.21 1.03 − 1.37 0.013
Platelet count 0.98 0.95 − 1.00 0.073 0.98 0.95 − 1.01 0.147
FDP 1.00 1.00 − 1.00 0.586 1.00 1.00 − 1.00 0.314
PT ratio 1.34 1.11 − 1.68 0.002 1.34 1.04 − 1.79 0.018
AT activity 0.99 0.98 − 0.99 0.000 0.99 0.98 − 1.00 0.003
AT antithrombin, CI confidence interval, FDP fibrinogen/fibrin degradation
products, JAAM-DIC Japanese Association for Acute Medicine-disseminated
intravascular coagulation, OR odds ratio, PT prothrombin time, SIRS systemic
inflammatory response syndrome
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sufficiently stringent. Yoshimura et al. [4] suggested that
recombinant thrombomodulin might be effective when
the baseline APACHE II score was 24 or more.
Another problem with the JAAM-DIC criteria is the
SIRS score. This item is no longer used for the diagnosis
of sepsis [10]. Moreover, the SIRS score does not reflect
coagulation/fibrinolysis disorders directly. Umemura et
al. [1] demonstrated that anticoagulant therapies were
effective in sepsis patients with coagulation dysfunction
but not in those without dysfunction. In 2015, the JSTH
proposed new DIC diagnostic criteria using the platelet
count, PT ratio, FDP, some molecular markers, and anti-
thrombin activity (https://www.jstage.jst.go.jp/article/
jjsth/25/5/25_629/_pdf ). In the JSTH criteria, the cut-off
value for antithrombin was set at 70 % without any sup-
portive data. Our data demonstrated that the mortality
of patients with a baseline antithrombin activity of less
than 70 % was 35.5 %, which might be sufficiently severe
to warrant the use of recombinant thrombomodulin.
Therefore, we adopted an antithrombin activity of more
than 70 % as a cut-off value. As mentioned before, the
efficacy of anticoagulants depends on the severity of the
sepsis [4, 26, 27], and the efficacy of recombinant throm-
bomodulin was revealed in a population in which the
post-treatment mortality was 20 % or more [4, 28], but
it might not be efficient in a population with a mortality
rate of less than 20 % [4, 26]. Thus, we think that the
modified version of the JAAM-DIC might be suitable for
identifying appropriate candidates for recombinant
thrombomodulin treatment.
The present study had several limitations. First, many of
the subjects analyzed in this study met the JAAM-DIC cri-
teria at baseline. To propose new diagnostic criteria, an
analysis of sepsis patients who might develop DIC is
needed. Further validation should be done in subjects with
or without DIC. Second, all patients included had sepsis-
associated coagulopathy whereas other potential causes of
DIC such as trauma, surgery, and burns were not evalu-
ated. Future studies should examine the value of the
modified scoring system in these DIC populations. Third,
the cut-off value for antithrombin activity was empirically
Table 3 Relationship between the 28-day mortality, JAAM-DIC
criteria, and antithrombin activity
Cut-off value Odds ratio 95 % CI P value
SIRS score ≧3 1.480 1.080 − 2.027 0.014
Platelet count
(×109/L)
<120 1.242 0.821 − 1.880 0.304
<80 1.277 0.938 − 1.739 0.121
FDP (mg/L) ≧10 0.803 0.554 − 1.164 0.247
≧25 0.791 0.591 − 1.058 0.113
PT ratio ≧1.2 1.658 1.170 − 2.348 0.004
AT activity (%) <70 1.522 1.065 − 2.176 0.021
AT antithrombin, CI confidence interval, FDP fibrinogen/fibrin degradation
products, JAAM-DIC Japanese Association for Acute Medicine-disseminated
intravascular coagulation, OR odds ratio, PT prothrombin time, SIRS systemic
inflammatory response syndrome
Table 4 Comparison of mortality differences according to
antithrombin (AT) activity
Mortality P value
AT activity <40 % 45.5 % (85/187) <0.0001
AT activity ≧40 % 29.8 % (188/632)
AT activity <50 % 39.3 % (133/339) 0.0026
AT activity ≧50 % 29.2 % (140/480)
AT activity <60 % 36.6 % (180/492) 0.0155
AT activity ≧60 % 28.4 % (93/327)
AT activity <70 % 35.5 % (221/623) 0.0205
AT activity ≧70 % 26.5 % (52/196)
Fig. 1 Comparison of patient distribution and mortality between
subjects with a systemic inflammatory response syndrome (SIRS) score
≧ 3 and those with an antithrombin (AT) activity <70 %. Though the
number of patients was larger in the category with an antithrombin
activity <70 % than in the category with a SIRS score ≧3, the mortality
rate was similar. The mortality rate in the category with an
antithrombin activity <70 % was 35.5 %, while that in the category
with an antithrombin activity ≧70 % was 26.5 %. The specificity for
death was 72.2 % for the category with a SIRS score ≧3 and 73.5 % for
the category with an antithrombin activity <70 %. DIC disseminated
intravascular coagulation
Table 5 Number of patients diagnosed with DIC, SOFA score,







DIC JAAM-DIC 706 7 (4 − 11) 14.7 34.6
Modified JAAM-
DIC
706 7 (4 − 11) 14.7 34.8
No
DIC
JAAM-DIC 113 7 (4 − 11) 13.3 25.7
Modified JAAM-
DIC
113 7 (5 − 11) 13.3 23.9
DIC disseminated intravascular coagulation, JAAM Japanese Association for
Acute Medicine, SOFA sequential organ failure assessment
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fixed at 70 %; however, the optimal cut-off should be de-
termined using a larger number of subjects. Fourth, all the
patients were treated with recombinant thrombomodulin.
While it might be better to use data from subjects who
did not receive anticoagulant therapy, such a study would
be difficult to perform in Japan. Therefore, we utilized
data from patients who uniformly received anticoagulant
therapy as needed. Fifth, because fibrinogen and D-dimer
data were not available, we could not compare the modi-
fied JAAM-DIC criteria with the ISTH or other diagnostic
criteria. Such comparisons should be done in the future.
In summary, discriminating between simple coagulop-
athy and DIC is essential for deciding the proper timing
of anticoagulant therapy. The modified JAAM-DIC diag-
nostic criteria were able to identify the patients who
might benefit from anticoagulant therapy. The useful-
ness of these new diagnostic criteria should be examined
in a prospective study.
Conclusions
Since the SIRS category is no longer used for the diag-
nosis of sepsis, the JAAM-DIC diagnostic criteria should
be modified. The replacement of a SIRS score ≧3 with
an antithrombin activity level <70 % makes it possible to
discriminate a more coagulation disorder-specific popu-
lation. Thus, the modified version of the JAAM-DIC
diagnostic criteria may be useful for identifying candi-
dates for anticoagulant therapy among patients with
sepsis.
Key messages
 JAAM-DIC diagnostic criteria should be modified
since the SIRS score has been losing its prognostic
power and is no longer used for the diagnosis of
sepsis.
 The replacement of a SIRS score ≧3 with an
antithrombin activity level <70 % may make it
possible to discriminate proper candidates for
anticoagulant therapy among patients with sepsis.
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